CL2004001431A1 - Compuestos derivados de 1-(alquilaminoalquil-/pirrolidin-/piperidinil)-2,2-difenilacetamida, antagonistas del receptor muscarinico; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica y uso del - Google Patents

Compuestos derivados de 1-(alquilaminoalquil-/pirrolidin-/piperidinil)-2,2-difenilacetamida, antagonistas del receptor muscarinico; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica y uso del

Info

Publication number
CL2004001431A1
CL2004001431A1 CL200401431A CL2004001431A CL2004001431A1 CL 2004001431 A1 CL2004001431 A1 CL 2004001431A1 CL 200401431 A CL200401431 A CL 200401431A CL 2004001431 A CL2004001431 A CL 2004001431A CL 2004001431 A1 CL2004001431 A1 CL 2004001431A1
Authority
CL
Chile
Prior art keywords
compounds
difenylacetamide
alquilaminoalquil
piperidinil
pirrolidin
Prior art date
Application number
CL200401431A
Other languages
English (en)
Inventor
Mathai Hughes Adm Li Li Mammen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CL2004001431A1 publication Critical patent/CL2004001431A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION TIENE COMO OBJETO COMPUESTOS DE FORMULA I DONDE R1 -R5 Y a-e TIENEN LOS VALORES QUE SE DEFINE EN LA ESPECIFICACION O SALES O SOLVATOS O ESTEREOISOMEROS ACEPTABLES PARA USO FARMACEUTICO DE LOS MISMOS. LA INVENCION TAMBIEN TIENE COMO OBJETO COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS, PROCESOS E INTERMEDIARIOS DE UILIDAD EN LA PREPARACION DICHOS COMPUESTOS Y METODOS PARA TRATAR ESTADOS DE ENFERMEDAD MEDIADOS POR LOS RECEPTORES MUSCARINICOS UTILIZAZNDO DICHOS COMPUESTOS.
CL200401431A 2003-06-13 2004-06-09 Compuestos derivados de 1-(alquilaminoalquil-/pirrolidin-/piperidinil)-2,2-difenilacetamida, antagonistas del receptor muscarinico; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica y uso del CL2004001431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47845603P 2003-06-13 2003-06-13

Publications (1)

Publication Number Publication Date
CL2004001431A1 true CL2004001431A1 (es) 2005-03-18

Family

ID=33563773

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401431A CL2004001431A1 (es) 2003-06-13 2004-06-09 Compuestos derivados de 1-(alquilaminoalquil-/pirrolidin-/piperidinil)-2,2-difenilacetamida, antagonistas del receptor muscarinico; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica y uso del

Country Status (22)

Country Link
US (5) US7183292B2 (es)
EP (1) EP1633707A1 (es)
JP (1) JP2007507496A (es)
KR (1) KR20060017541A (es)
CN (2) CN100406435C (es)
AR (1) AR044676A1 (es)
AU (1) AU2004253869B2 (es)
BR (1) BRPI0411358A (es)
CA (1) CA2525801A1 (es)
CL (1) CL2004001431A1 (es)
CO (1) CO5650231A2 (es)
IS (1) IS8155A (es)
MA (1) MA27852A1 (es)
MX (1) MXPA05013256A (es)
MY (1) MY139290A (es)
NO (1) NO20060191L (es)
NZ (1) NZ543805A (es)
PE (1) PE20050282A1 (es)
RU (1) RU2337095C2 (es)
TW (1) TW200510298A (es)
WO (1) WO2005003090A1 (es)
ZA (1) ZA200509942B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
WO2005087763A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
US7071224B2 (en) * 2004-03-11 2006-07-04 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192206A (en) 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-aminoalkyl)-3, 3-disubstitutedn-hydrocarbon-2-pyrrolidinones and corresponding-2-thionpyrrolidinones
US3192221A (en) 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-thionpyrrolidinones and production thereof
US3192210A (en) 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-thionpyrrolidinones
US3247222A (en) 1962-12-26 1966-04-19 Robins Co Inc A H Alpha (nu-hydrocarbonpyrrolidyl-3-) alpha, alpha carbocyclic arylacetamides
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US3984557A (en) 1974-12-26 1976-10-05 A. H. Robins Company, Incorporated Antiarrhythmia compositions and methods
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
JPS57175165A (en) * 1981-04-21 1982-10-28 Tokyo Tanabe Co Ltd Novel 1,4-dihydropyridine-3,5-dicarboxylic diester derivative and its salt
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
IL76583A (en) 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
EP0211595B1 (en) 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
EP0235463A3 (en) 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
US4810713A (en) 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
IN163948B (es) * 1986-01-17 1988-12-10 Robins Co Inc A H
US5932594A (en) 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
US5070087A (en) 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5486527A (en) 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
US5607950A (en) 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
GB9000301D0 (en) 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
JP2997705B2 (ja) * 1990-08-01 2000-01-11 株式会社ネオス 静電荷像現像用トナー
JP3005024B2 (ja) * 1990-08-03 2000-01-31 株式会社ネオス 摩擦帯電付与部材
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
DK0617610T3 (da) 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
SE9202218D0 (sv) * 1992-07-22 1992-07-22 Kabi Pharmacia Ab Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
EP0823423B1 (en) 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
JPH0971048A (ja) * 1995-09-06 1997-03-18 Fuji Photo Film Co Ltd 感熱記録材料
DE69615214T2 (de) 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate
WO1998054167A1 (en) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Indole compounds
CN1268938A (zh) 1997-07-24 2000-10-04 三菱东京制药株式会社 氨基环烷烃化合物
JPH11100366A (ja) 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
JP2002517464A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド ムスカリン性レセプターアンタゴニスト
WO2000004103A1 (en) 1998-07-14 2000-01-27 Seiko Epson Corporation Sublimation transfer ink jet recording method and ink composition for use therein
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6403810B2 (en) 2000-07-10 2002-06-11 Hoffmann-La Roche Inc. Thiophene derivatives
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (ja) 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
PE20050973A1 (es) 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
WO2005087763A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
US7071224B2 (en) 2004-03-11 2006-07-04 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound

Also Published As

Publication number Publication date
CN100406435C (zh) 2008-07-30
US7183292B2 (en) 2007-02-27
PE20050282A1 (es) 2005-04-29
NZ543805A (en) 2009-06-26
CN1805927A (zh) 2006-07-19
JP2007507496A (ja) 2007-03-29
US20070078163A1 (en) 2007-04-05
AR044676A1 (es) 2005-09-21
AU2004253869A1 (en) 2005-01-13
CO5650231A2 (es) 2006-06-30
US20080146649A1 (en) 2008-06-19
ZA200509942B (en) 2006-12-27
KR20060017541A (ko) 2006-02-23
MA27852A1 (fr) 2006-04-03
MXPA05013256A (es) 2006-03-09
EP1633707A1 (en) 2006-03-15
BRPI0411358A (pt) 2006-07-25
US20040254219A1 (en) 2004-12-16
TW200510298A (en) 2005-03-16
US7638639B2 (en) 2009-12-29
MY139290A (en) 2009-09-30
RU2337095C2 (ru) 2008-10-27
US20070135482A1 (en) 2007-06-14
IS8155A (is) 2005-11-28
US7351718B2 (en) 2008-04-01
US20080161577A1 (en) 2008-07-03
RU2006101151A (ru) 2006-06-27
WO2005003090A1 (en) 2005-01-13
CN101108809B (zh) 2010-07-14
CN101108809A (zh) 2008-01-23
US7351717B2 (en) 2008-04-01
US7615566B2 (en) 2009-11-10
NO20060191L (no) 2006-03-10
AU2004253869B2 (en) 2010-02-18
CA2525801A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
UY28760A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
UY28186A1 (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos.
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
PA8556901A1 (es) Nuevos derivados de piperazina
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
UY28342A1 (es) Nuevos compuestos
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
ECSP078018A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
PA8845601A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)